|

|

| U.S. Nuclear
Power Reactor Map
iOSAT™
received its approval from the US Food and Drug Administration in 1982,
and is the only full-strength tablet for radiation blocking which may
legally be sold in the US. Only iOSAT™ has passed all FDA tests for purity, quality, safety and efficacy.
Meets all FDA requirements
for potassium iodide as a radiation protective, and is labeled and packaged
in accordance with US government guidelines.
Has demonstrated all quality controls and passed all FDA requirements
for purity, quality, safety, efficacy.
Comes full strength (130
mg of potassium iodide per tablet) in accordance with FDA demands for complete
thyroid blocking.
|
|
|
|
|
Note: the US Food and Drug Administration (FDA) has tested and approved
iOSAT and only one other full-strength brand of potassium iodide
(Thyro-block) for sale for radiation protection.
However, despite the obvious illegality, there are numerous companies
selling unapproved tablets which have not passed FDA manufacturing
requirements or demonstrations for safe and effective use in a
radiation emergency.
- Any tablets which contain potassium iodate (not iodide);
- Tablets labeled as nutritional supplements;
- Tablets containing ["microgram" not "milligram") amounts of potassium iodide;
- Any product containing either less than ten, or more than 14, tablets;
- Tablets sold under the name of:
- Rad Block,
- No-Rad,
- Pro KI,
- Rad Safe,
- Rad Guard,
- KI4U




|
|
|

|

| U.S. Power Reactor
Radiation Zones
Contains no potassium iodate
or other adulterants. Contains only pure potassium iodide as the active
ingredient.
IOSAT [potassium iodide]
Is manufactured in the United States under strict FDA GMP guidelines,
and
holds an approved New Drug Application (NDA).
IOSAT [potassium iodide]
Was the first product of its kind (since 1982) and is the only product that
can be purchased by local, state and federal governments.
Is widely purchased by nuclear utilities.
IOSAT [potassium iodide]
offers unit dose packaging for maximum shelf-life and allows for individual
tablet distribution without fear of loss of packaging integrity.
|
|
|